Sherri Lemmer
Analyst · Dan Jacome with the Sidoti & Company. Please go ahead
Thank you, Mike. Good morning. Net sales for the fourth quarter of 2014 were $89.9 million versus the prior year fourth quarter of $91.1 million. You may recall that the fourth quarter of 2013 was the first full quarter following the complete launch of our new DublNature family of products and there were significant customer volume and buying under the rebate program in place following the full launch of those products and as 2013 came to a close. Fourth quarter 2014 shipment trends, while particularly strong in our strategic product categories, where shipments were up over 1% compared to the fourth quarter of 2013, return to a more historical seasonality pattern and marked the second highest number of cases shipped for any fourth quarter in the company’s history. For the full year, net sales were $352 million in 2014, compared to $348.6 million for the full year of 2013. Full year shipments were 17 million cases, an increase of 1.6% over the full year 2013 at 16.7 million cases. As Mike noted from an EBITDA perspective adjusting for non-recurring item, we reported results of $14.9 million or 16.6% adjusted EBITDA margins, compared to $11.6 million or 12.7% EBITDA margin in the fourth quarters of 2014 and ’13, respectively. Full year adjusted EBITDA was $44.2 million and $36.9 million in 2014 and 2013, respectively, again a year-over-year improvement of approximately 20%. Bridging the fourth quarter of 2013 to the fourth quarter of 2014, benefits from the July 1st price action and the strategic mix of product sold that exceed 50% for the first time were offset by an unfavorable impact of about $600,000 due to the change in the Canadian exchange rate quarter-over-quarter. As mentioned earlier, sales volume was down quarter-over-quarter about 2.9%, driven by support product category volume. Operationally, as expected, we continue to see improvement in every areas, paper machines to converting, partially offsetting the fourth quarter improvement, our cost associated with margin enhancement initiative projects. Selling, general and administrative expenses were also lower than the prior year, in part due to the unusual pattern of initiatives that occurred in the prior year, following the complete launch of our DublNature products and in part due to lower proxy [defense] [ph] costs. These two elements accounted for about $1.3 million of the quarter-over-quarter benefit. Wages and benefits and other impact due to restructuring and narrowing the focus of our business, offset by cost to support the margin enhancement initiative projects accounted for the balance of the improvement quarter-over-quarter. Turning to adjusted earnings per share, we finished the fourth quarter of 2014 with after tax net earnings from continuing operations of approximately $705,000 or $0.01 per share, compared to an after tax adjusted net loss of approximately $289,000 or breakeven earnings per share for last years fourth quarter. On a full year basis, after tax adjusted net losses were approximately $4.9 million or $0.10 per share and $7.4 million or $0.15 per share in 2014 and 2013, respectively. We reviewed most of the quarter-over-quarter impact at the EBITDA level on the last slide, so now I will focus more on the full year comparison. From a sales price and mix perspective, competitive pricing pressure and the unfavorable impact of the Canadian exchange rate was mitigated by the July 1, 2014 price action and continued improvement in the mix of our product sold with a higher composition of strategic versus support products. As mentioned, full year sales volume improved 1.6% or about twice that of the estimated North American away from home market demand and contributed about $0.02 per share for the full year. Weather related impacts of about $0.01 per share were experienced in the first quarter of 2014. Year-over-year improvement in operations as we gained experience on a new manufacturing and converting asset throughout 2013 and ’14, as well as the strong overall performance and focus on cost containment activities in our Kentucky, Ohio and Wisconsin locations contributed $0.16 per share to our year-over-year improvement. And higher interest expense as a result of higher debt levels and cost of debt following our July 30, 2014 refinancing was unfavorable to year-over-year results by $0.02 per share. In summary, 2014 was certainly a year of change from a financial perspective. We demonstrated sequential quarter-over-quarter financial improvement as we move through 2014 from Q1 to Q4 and delivered a 20% improvement in EBITDA year-over-year. Sales and shipments increased and our operational cost structure improved. We reduced adjusted selling, general and administrative costs by approximately $4 million or about 1% of net sales. We are targeting adjusted SG&A of about 12.5% of net sales and on an adjusted basis we were about 13.2% in SG&A to net sales for the full year 2014. We prudently managed key elements of cash spend including our capital spend. And during 2014, we diligently reviewed projects and project spending. The result was total capital spend of $16.4 million, compared to a third quarter estimate of $23 million and a prior year of $37.5 million, and we refinanced long-term debt structure of the company in mid 2014. With that, I'll turn the call over to Matt. Matt?